Taking stock of the drug industry, from the lab to the medicine chest

July 15, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe Opinion: Medicare drug pricing rules will delay access to promising therapies Expert cites the history of tofacitinib (Xeljanz) as an example of an innovative treatment that could now be stifled under new Medicare drug pricing rules. By Peter Rheinstein Vertex sues U.S. government over access to fertility support services for Casgevy patients CRISPR treatment for sickle cell disease carries a high risk of infertility. Vertex wants to preserve patient fertility, but a federal rule poses problems. By Megan Molteni STAT+ | Early data from Lexeo's gene therapy for rare heart disease shows promise Lexeo said Monday that a gene therapy targeting cardiac complications of Friedrich's ataxia reduced signs of heart disease. By Jason Mast Lisa Maree Williams/Getty Images Opinion: Functional neurological disorder is not an appropriate diagnosis for people with long Covid Some say the existing diagnosis of functional neurological disorder offers a good explanation for long Covid. It doesn't. By David Tuller, Mady Hornig, and David Putrino

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser